Trial of CTX 1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs CTX 1301 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics; Proof of concept
- 10 Jul 2017 Status changed from recruiting to completed, according to a Cingulate Therapeutics media release.
- 31 May 2017 According to a Cingulate therapeutics media release, dosing has been initiated in this trial, and the company anticipates reporting findings from this trial in the third quarter of 2017.
- 24 Nov 2016 New trial record